The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Open accessAbstract
Background Approximately 85% of nasal polyps (NPs) in white subjects are characterized by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival. Objective We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal polyposis. Methods Thirty patients with severe nasal polyposis (grade 3 or 4 or recurrent after surgery) refractory to corticosteroid therapy were randomized in a double-blind fashion to receive either 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (n = 20) or placebo (n = 10). Change from baseline in NP score was assessed monthly until 1 month after the last dose (week 8). Computed tomographic scans were also performed at week 8. Results Twelve of 20 patients receiving mepolizumab had a significantly improved NP score and computed tomographic scan score compared with 1 of 10 patients receiving placebo at week 8 versus baseline. Conclusion Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These biological treatments have a potentially major effect on NO and the size of NP.”
From Position Paper on Nasal Obstruction: Evaluation and Treatment (2018) · cites this paper as [182]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020) · Rhinology journal · doi:10.4193/rhin20.600 · Cited by 5,882
Self-citationA Novel Transcription Factor, T-bet, Directs Th1 Lineage Commitment
Szabo, S. J., Kim, S. T., Costa, G. L., Zhang, X., Fathman, C. G., & Glimcher, L. H. (2000) · Cell · doi:10.1016/s0092-8674(00)80702-3 · Cited by 3,589
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W. R., Sousa, A. R., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,873
Self-citationInterleukin-5, eosinophils, and disease
Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.3101 · Cited by 860
Differentiation of chronic sinus diseases by measurement of inflammatory mediators
Zele, T. V., Claeys, S., Gevaert, P., Maele, G. V., Holtappels, G., Cauwenberge, P. V., & Bachert, C. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01225.x · Cited by 775
Self-citationA Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma
Flood-Page, P. T., Swenson, C. A., Faiferman, I., Matthews, J. G., Williams, M. J. A., Brannick, L., Robinson, D. S., Wenzel, S. E., Busse, W. W., Hansel, T. T., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-085oc · Cited by 750
Total and specific IgE in nasal polyps is related to local eosinophilic inflammation
Bachert, C., Gevaert, P., Holtappels, G., Johansson, S. G. O., & Cauwenberge, P. V. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.112374 · Cited by 702
Self-citationDifferent types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease
Zhang, N., Zele, T. V., Perez-Novo, C. A., Bruaene, N. V., Holtappels, G., Ruyck, N. D., Cauwenberge, P. V., & Bachert, C. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.07.008 · Cited by 621
Self-citationCao, P., Li, H., Wang, B.-F., Wang, S.-B., You, X., Cui, Y., Wang, D. Y., Desrosiers, M. Y., & Liu, Z. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.05.017 · Cited by 617
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J., Weller, P. F., Simon, H., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070812 · Cited by 590
Flagged first, then by citations
1 of the 31 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 629
Phase three studies of biologics for severe asthma: could do better?
Robinson, D. S., Kariyawasam, H. H., & Heaney, L. G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01108-2017 · Cited by 9
Chronic rhinosinusitis and omalizumab: eosinophils not IgE predict treatment response in real-life
Sahota, J., Bidder, T., Livingston, R., Robinson, D. S., Lund, V. J., Su, M. P., & Kariyawasam, H. H. (2018) · Rhinology online · doi:10.4193/rhinol/18.077 · Cited by 9
Maza-Solano, J. M., Calvo‐Henríquez, C., Alobid, I., Álvarez-Cendrero, M., Palomares, Ó., Moreno‐Luna, R., Santos-Pérez, J., García, J. G., & Sánchez‐Gómez, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237056 · Cited by 9
Phan, N. T., Cabot, P. J., Wallwork, B. D., Cervin, A., & Panizza, B. J. (2015) · The Journal of Laryngology & Otology · doi:10.1017/s0022215115001322 · Cited by 9
Biologic Therapies for Immunoglobulin E–mediated Food Allergy and Eosinophilic Esophagitis
Otani, I. M., & Nadeau, K. C. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.01.010 · Cited by 9
Understanding the Role of Neutrophils in Refractoriness of Chronic Rhinosinusitis With Nasal Polyps
Lan, F., & Zhang, L. (2019) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2020.12.1.1 · Cited by 9
Rinitis alérgica en pediatría: recomendaciones para su diagnóstico y tratamiento
Agüero, C. A., Sarraquigne, M. P., Parisi, C. A. S., Mariño, A. I., López, K., Porfirio, B. M., Sasia, L. V., Lozano, A., Martijena, M. D. P. B., Gervasoni, M. E., et al. (2023) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2022-02894 · Cited by 8
Biologics and Surgery in Chronic Rhinosinusitis With Nasal Polyps: A Comparative Outcomes Analysis
Narendran, N. H., Samargandy, S. A., Volpe, S., Patterson, J., Gutama, B. W., & Chang, E. H. (2025) · American Journal of Rhinology and Allergy · doi:10.1177/19458924251366569 · Cited by 8
Li, T., Yin, J., Yang, Y., Wang, G., Zhang, Y., & Song, X. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2231150 · Cited by 9
Huriyati, E., Darwin, E., Yanwirasti, Y., & Wahid, I. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.327 · Cited by 8
Priyadharshini, V. S., Jiménez-Chobillón, M. A., de Graaf, J., Porras‐Gutiérrez‐de‐Velasco, R., Gratziou, C., Jiménez, F. R., & Teran, L. M. (2021) · Biomolecules · doi:10.3390/biom11081092 · Cited by 8
A systematic review and meta-analysis of the role of doxycycline in chronic rhinosinusitis
Chan, D., Ooi, E. H., & Khalid, O. (2022) · The Journal of Laryngology & Otology · doi:10.1017/s0022215122001803 · Cited by 8
Inflammatory and Effector Cells/Cell Migration
Davis, B. P., & Rothenberg, M. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-29875-9.00005-7 · Cited by 8
Workforce Considerations, Training, and Diseases of the Asia-Pacific Region
Smith, J. D. S., & Tan, K. L. (2018) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2018.01.010 · Cited by 8
Biologics and the treatment of chronic rhinosinusitis
Kern, R. C. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.11.021 · Cited by 8
ARIA-Italy multidisciplinary consensus on nasal polyposis and biological treatments: Update 2025
Lombardi, C., Canevari, F. R., Bagnasco, D., Bilò, M. B., Canonica, G. W., Caruso, C., Castelnuovo, P., Cecchi, L., Calcinoni, O., Carone, M., et al. (2025) · World Allergy Organization Journal · doi:10.1016/j.waojou.2025.101058 · Cited by 7
How to Assess, Control, and Manage Uncontrolled CRS/Nasal Polyp Patients
Sivasubramaniam, R., & Harvey, R. J. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0728-8 · Cited by 7
The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis
Aldinger, J. P., Dobyns, T., Lam, K. K., & Han, J. K. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1962282 · Cited by 7
Okano, M., Fujiwara, T., Kariya, S., Higaki, T., Makihara, S., Haruna, T., Noyama, Y., Koyama, T., Omichi, R., Orita, Y., et al. (2015) · Allergology International · doi:10.1016/j.alit.2015.08.005 · Cited by 7
Tidemandsen, J. E., Backer, V., Homøe, A., Jensen, T. H. L., Aanæs, K., Meteran, H., Hostrup, M., Moesgaard, L., Haase, C. H., & Gibson, P. G. (2025) · International Forum of Allergy & Rhinology · doi:10.1002/alr.70073 · Cited by 6
Persistence of Sinonasal Disease Despite Mepolizumab
Rowan, N. R., & Naclerio, R. M. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.01.049 · Cited by 6
Novel diagnostic approaches and biological therapeutics for intrinsic asthma
Vennera, M. D. C., & Picado, C. (2014) · International Journal of General Medicine · doi:10.2147/ijgm.s45259 · Cited by 6
Chronic rhinosinusitis: an update on current pharmacotherapy
Adriaensen, G. F. J. P. M., & Fokkens, W. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.837450 · Cited by 6
Phenotyping, endotyping and clinical decision-making
Fokkens, W. J. (2016) · Rhinology Journal · doi:10.4193/rhin16.402 · Cited by 6
Immunomodulators in the Treatment of Nasal Polyposis
Halderman, A. A., & Lane, A. P. (2016) · Advances in oto-rhino-laryngology · doi:10.1159/000445141 · Cited by 6
Outcomes in Medical and Surgical Treatment of Nasal Polyps
Jafari, A., & DeConde, A. S. (2016) · Advances in oto-rhino-laryngology · doi:10.1159/000445155 · Cited by 6
Wagenmann, M., Scheckenbach, K., & Chaker, A. M. (2017) · ORL · doi:10.1159/000455721 · Cited by 6
Pavord, I. D., & Hanania, N. A. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.03.010 · Cited by 6
Pharmacological, Technological, and Digital Innovative Aspects in Rhinology
Ruggiero, R., Motta, G., Massaro, G., Rafaniello, C., Corte, A. D., Angelis, A. D., Capuano, A., Motta, G., & Rossi, F. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.732909 · Cited by 6
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis
Liu, X., Charn, T. C., & Wang, D. Y. (2023) · Immunotherapy · doi:10.2217/imt-2023-0026 · Cited by 5
Saccardo, T., Roccuzzo, G., Tessari, N., Zampollo, S., Fontana, A., Scarpa, B., Nicolai, P., & Ottaviano, G. (2025) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-025-09725-x · Cited by 5
Carney, A. S., & Smith, P. K. (2023) · American Journal of Rhinology and Allergy · doi:10.1177/19458924221149270 · Cited by 5
Shen, Y., Guan, D., Gu, Y., Zheng, B., Ke, X., Hong, S., & Yang, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112462 · Cited by 5
A new treatment for chronic rhinosinusitis with nasal polyps
Stevens, W. W. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32133-6 · Cited by 5
Hershey, G. K. K., Sherenian, M. G., & Baye, T. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-80912-2.00002-0 · Cited by 5
Bagnasco, D., Savarino, E. V., Yacoub, M., Braido, F., Candeliere, M. G., Giannini, E. G., Passalacqua, G., & Marabotto, E. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092359 · Cited by 5
Eosinophilic asthma with chronic rhinosinusitis/nasal polyps and biologic agents
Yılmaz, İ. (2019) · Tuberkuloz ve Toraks · doi:10.5578/tt.68953 · Cited by 5
INTERLEUKIN-5 IS A NEW TARGET IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Beketova, T. V., & Arseniev, E. V. (2020) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2020-321-329 · Cited by 5
Immunological and microRNA Features of Allergic Rhinitis in the Context of United Airway Disease
Naydenova, K., Dimitrov, V. D., & Velikova, T. V. (2021) · Sinusitis · doi:10.3390/sinusitis5010005 · Cited by 5
Hagin, D., Shacham, Y., Kivity, S., & Benor, S. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.07.045 · Cited by 5
Courey, M. S., & Pletcher, S. D. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00049-x · Cited by 5
Ley-Tomas, J. J., Xicotencatl-Tellez, A. M., García-Cruz, M. L., & Jiménez-Chobillón, M. A. (2024) · Frontiers in Allergy · doi:10.3389/falgy.2024.1462985 · Cited by 4
Fan, J., Daniels, W., Pascual, A., Ryu, C., Sarafan, M., Tepedino, M. S., Voegels, R. L., Fornazieri, M. A., Sin, D. D., Pezato, R., et al. (2025) · International Archives of Otorhinolaryngology · doi:10.1055/s-0044-1801316 · Cited by 4
Polyps, asthma, and allergy: what's new
Terzakis, D., & Georgalas, C. (2016) · Current Opinion in Otolaryngology & Head & Neck Surgery · doi:10.1097/moo.0000000000000323 · Cited by 4
Biomarkers in Chronic Rhinosinusitis with Nasal Polyp: Personalized Medicine Based on Endotype
Song, Y., & Cho, S. (2019) · Korean Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.3342/kjorl-hns.2019.00332 · Cited by 4
A Case of Eosinophilic Cystitis treated with Mepolizumab
Alzaabi, S., & Nasir, M. (2023) · New Emirates Medical Journal · doi:10.2174/04666230313100005 · Cited by 4
Kariyawasam, H. H., Langan, D., & Rimmer, J. (2025) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s467250 · Cited by 4
Inflammatory Disorders Associated with Allergy
Corren, J. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.01.001 · Cited by 4
Rhinosinusitis and Nasal Polyps
Bachert, C., Calus, L., & Gevaert, P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-323-08593-9.00044-9 · Cited by 4
Self-citationSchmitt, N. C., Monfared, A. S., & Wise, S. K. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2021.04.001 · Cited by 4
Current Evidence for Biologic Therapy in Chronic Rhinosinusitis with Nasal Polyposis
Ramaswamy, U., Melder, K. L., Patel, V. A., & Lee, S. E. (2021) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2021.04.007 · Cited by 4
Jung, D. H. H., Elena-Pérez, S., Garcı́a-Sánchez, A., Estravís, M., Isidoro‐García, M., Sanz, C., & Davila, I. J. (2023) · Biomedicines · doi:10.3390/biomedicines11071966 · Cited by 4
Evidence and evidence gaps in therapies of nasal obstruction and rhinosinusitis
Rotter, N. (2016) · PubMed · doi:10.3205/cto000133 · Cited by 4
Rhinology Future Debates 2017 by EUFOREA : Novel treatments and surgical solutions in rhinology
Fokkens, W. J., Pugin, B., Bachert, C., Bousquet, J. J., Joos, G., Louis, R. E., Pilette, C., Pfaar, O., Price, D. B., Prokopakis, E. P., et al. (2018) · Clinical Otolaryngology · doi:10.1111/coa.13184 · Cited by 4
Self-citationRole of the TAp63 Isoform in Recurrent Nasal Polyps
Terrinoni, A., Palombo, R., Pitolli, C., Caporali, S., Berardinis, R. D., Ciccarone, S., Lanzillotta, A., Mauramati, S., Porta, G., Minieri, M., et al. (2019) · Folia Biologica · doi:10.14712/fb2019065040170 · Cited by 4
Al‐Harbi, T., Alsubaie, N. A., & Alroqi, A. S. (2025) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-025-09559-7 · Cited by 3
Cihanbeylerden, M., Kayıkçı, H., Tüccar, Ç., Ustaoğlu, A. P., Damadoğlu, E., Karakaya, G., & Kalyoncu, A. F. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.07.038 · Cited by 3
Nevel, S. V., Zhang, N., Xu, Z., Blauwblomme, M., Vandewalle, E., Holtappels, G., Ruyck, N. D., Nieuwerburgh, F. V., Vanhee, S., Gevaert, P., et al. (2025) · Clinical and Translational Allergy · doi:10.1002/clt2.70117 · Cited by 3
Self-citationEFFICACY OF RESLIZUMAB IN THE TREATMENT OF ASTHMA AND COMORBID CHRONIC RHINOSINUSITIS WITH POLYPS
Бойко, Н. В., Stagnieva, I. V., Лодочкина, О. Е., Киселев, В. В., & Bykova, V. V. (2021) · The Bulletin of Contemporary Clinical Medicine · doi:10.20969/vskm.2021.14(6).22-27 · Cited by 3
Villamañán, E., Laorden, D., Ibáñez, M. E., Vecillas, L. D. L., Carpio, C., Alfonso, C., Domínguez‐Ortega, J., Romero, D., Quirce, S., & Álvarez-Sala, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145070 · Cited by 3
The role of inflammatory mediators in the pathogenesis of nasal polyposis: Literature review
Duda, R. (2015) · Romanian Journal of Rhinology · doi:10.1515/rjr-2015-0009 · Cited by 3
Nasal polyposis and asthma: the chest physician's view
van der Meer, A.-N., & Brinke, A. T. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10010116 · Cited by 3
Biologicals in der Rhinologie – Individualisierte Konzepte der Zukunft
Chaker, A. M. (2018) · Laryngo-Rhino-Otologie · doi:10.1055/s-0043-123484 · Cited by 3
Biologics in Chronic Rhinosinusitis with Nasal Polyps
Bachert, C. (2022) · Springer eBooks · doi:10.1007/978-981-16-0784-4_52 · Cited by 3
Self-citationMultidisciplinary Management of Pediatric Chronic Rhinosinusitis with Nasal Polyposis
Oh, E., Miller, J. E., & Lee, J. T. (2024) · Current Treatment Options in Allergy · doi:10.1007/s40521-024-00362-z · Cited by 3
Solak, G. T. V., Aksu, K., Akkale, Ö., Telli, O., Tuğlu, H. Ç., Çelik, F. D., & Yağdıran, M. (2024) · Allergy and Asthma Proceedings · doi:10.2500/aap.2024.45.240029 · Cited by 3
Cada, D. J., Bindler, R. J., & Baker, D. E. (2016) · Hospital Pharmacy · doi:10.1310/hpj5105-405 · Cited by 3
Kariya, S., Okano, M., & Nishizaki, K. (2015) · Advances in Cellular and Molecular Otolaryngology · doi:10.3402/acmo.v3.26601 · Cited by 3
Nasal polyposis and asthma: the otorhinolaryngologist's view
Fokkens, W. J., & Hellings, P. W. (2017) · European Respiratory Society eBooks · doi:10.1183/2312508x.10010016 · Cited by 3
IL-5Rα marks nasal polyp IgG4 and IgE-secreting cells in aspirin-exacerbated respiratory diseasePreprint
Buchheit, K. M., Dwyer, D. F., Ordovás-Montañés, J., Katz, H. R., Lewis, E. I., Lai, J., Bhattacharyya, N., Shalek, A. K., Barrett, N. A., Boyce, J. A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/527762 · Cited by 3
Sillanpää, S., & Numminen, J. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.659887 · Cited by 2
Phetpong, J., Seresirikachorn, K., Aeumjaturapat, S., Chusakul, S., Kanjanaumporn, J., Wongpiyabovorn, J., & Snidvongs, K. (2022) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22972 · Cited by 2
Mepolizumab for the treatment of chronic rhinosinusitis with nasal polyps in adults
Neposlan, J., Sowerby, L. J., & Biadsee, A. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2181794 · Cited by 2
Intrapolyp Steroid Injection for Nasal Polyposis: A Systematic Review and Network Meta‐Analysis
Albazee, E., Abu‐Zaid, A., Althaidy, M., & Alqunaee, M. (2024) · The Laryngoscope · doi:10.1002/lary.31969 · Cited by 2
Improving patient outcomes: Mepolizumab’s impact in IL-5-mediated diseases
Gothi, D., Narasimhan, R., Guleria, R., Chopra, M., Gvalani, A., & Hegde, R. (2025) · Lung India · doi:10.4103/lungindia.lungindia_442_24 · Cited by 3
Mechanisms, diagnosis, and treatment of olfactory dysfunction in rhinosinusitis
Zhu, H. H., Qu, S., Gong, M., Xiang, Y., Gan, S., Teng, Y., & Ye, D. (2025) · European journal of medical research · doi:10.1186/s40001-025-02740-y · Cited by 2
Kumar, N., Patel, E., Marino, M. J., & Lal, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1776180 · Cited by 2
Gelardi, M. (2026) · Cells · doi:10.3390/cells15040323 · Cited by 3
Liao, H., Qiu, C., Luo, Y., Chen, J., Qin, C., Quan, J., Liang, W., Qin, J., & Chen, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1746573 · Cited by 2
Zahedi, F. D., Abdullah, B., & Tantilipikorn, P. (2026) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000001146 · Cited by 2
Hamilton, J. D., Ferreira, M. A. R., Lim, W. K., Sidore, C., Wipperman, M. F., Ge, W., Song, X., Xia, C., Horowitz, J. E., Hooper, A. T., et al. (2026) · Allergy · doi:10.1111/all.70380 · Cited by 3
Mortuaire, G., Gengler, I. M., Balden, M., Capron, M., & Lefèvre, G. (2018) · Annales françaises d Oto-rhino-laryngologie et de Pathologie Cervico-faciale · doi:10.1016/j.aforl.2017.08.007 · Cited by 2
The use of biologics in personalized asthma care
Watchorn, D., & Holguin, F. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.2006635 · Cited by 2
Practical Review of Biologics in Chronic Rhinosinusitis With Nasal Polyps
Lee, K., Ryu, G., Yoo, S. H., Kim, Y. M., Mo, J., & Shin, S. (2021) · Journal of rhinology · doi:10.18787/jr.2021.00382 · Cited by 2
Efficacy and safety of monoclonal antibody therapy for chronic rhinosinusitis with nasal polyposis
Enache, R., Bejenariu, A. E., & Sarafoleanu, C. (2022) · Romanian Journal of Rhinology · doi:10.2478/rjr-2022-0024 · Cited by 2
Cakmak, M. E., & Yeğit, O. O. (2023) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2023.125768 · Cited by 2
Contemporary approaches to conservative treatment of chronic rhinosinusitis with nasal polyps
Георгиевна, П. Т., & Koryagin, F. N. (2023) · Medical alphabet · doi:10.33667/2078-5631-2023-5-63-66 · Cited by 2
Elzayat, S., Elgendy, A., Lasheen, H., El‐Deeb, M. E., Aouf, M., & Gehad, I. (2023) · The Journal of Laryngology & Otology · doi:10.1017/s0022215123001688 · Cited by 2
Adverse events of mepolizumab in the treatment of nasal polyps: A FDA database evaluation
Stephanian, B., Liu, K., Salazar, A. M., Saba, E. S., & Liang, J. Z. (2024) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2024.104517 · Cited by 2
Kayıkçı, H., Damadoğlu, E., Cihanbeylerden, M., Tüccar, Ç., Karakaya, G., & Kalyoncu, A. F. (2025) · Allergy and Asthma Proceedings · doi:10.2500/aap.2025.46.240105 · Cited by 2
Akiyama, K., Nakamura, H., Samukawa, Y., & Hoshikawa, H. (2020) · Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology) · doi:10.7248/jjrhi.59.139 · Cited by 2
The Pathogenesis of CRS: An Update
Bachert, C., Bahrani, N. A., Dousary, S. H. A., Crombruggen, K. V., Krysko, O., Perez-Novo, C. A., & Zhang, N. (2012) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-012-0002-5 · Cited by 2
Self-citationAdvances in upper airway diseases and allergen immunotherapy in 2011
Hsu, J., Saltoun, C. A., & Avila, P. C. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.01.050 · Cited by 2
Investigation of Revision Surgery for Chronic Sinusitis
Haruna, S. (2012) · Practica Oto-Rhino-Laryngologica · doi:10.5631/jibirin.105.899 · Cited by 2
Optimisation of Medical Management of Chronic Rhinosinusitis
Buckley, J., & Carrie, S. (2018) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-018-0211-7 · Cited by 2
Caulley, L., James, J., & Hopkins, C. L. (2020) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2020.3723 · Cited by 2
Nasal Immunity, Rhinitis, and Rhinosinusitis
Bachert, C., Krysko, O., Gevaert, P., Berings, M., Perez-Novo, C. A., & Crombruggen, K. V. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-415847-4.00100-2 · Cited by 2
Self-citationPhenotyping, endotyping and clinical decision-making
Fokkens, W. J. (2016) · Rhinology Journal · doi:10.4193/rhin.543e2 · Cited by 2
Canonica, G. W. (2017) · Journal of Otolaryngology-ENT Research · doi:10.15406/joentr.2017.07.00199 · Cited by 2
Xu, Y., Zheng, Y., Cao, M., Yang, W. J., Ren, J., Song, Y., Cheng, D., Wang, J., Huang, L., Xu, W., et al. (2019) · American Journal of Rhinology and Allergy · doi:10.1177/1945892419896540 · Cited by 2
Metadata
- Authors
- Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., & Bachert, C.
- Affiliations
- Ghent University (BE)
- University of Liège (BE)
- GlaxoSmithKline (United Kingdom) (GB)
- Corresponding author
- Gevaert, Philippe
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2011-11
- Volume
- 128
- Issue
- 5
- Pages
- 989-995.e8
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W1968876836
- Cited by
- 629
- References
- 31
- Citations by year
- 2026: 21 · 2025: 26 · 2024: 31 · 2023: 45 · 2022: 29 · 2021: 73 · 2020: 80 · 2019: 56 · 2018: 64 · 2017: 55 · 2016: 52 · 2015: 36 · 2014: 15 · 2013: 16 · 2012: 27
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- GlaxoSmithKline
- Fonds De La Recherche Scientifique - FNRS
- Fonds Wetenschappelijk Onderzoek
- Vlaamse regering
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Sinusitis and nasal conditions
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Keywords
- mepolizumab, IL-5 inhibition, nasal polyps, eosinophilic rhinosinusitis, humanized monoclonal antibody, corticosteroid-refractory disease, eosinophilia, anti-IL-5 therapy
- MeSH terms
- Double-Blind Method, Eosinophilia, Female, Humans, Male, Middle Aged, Nasal Polyps, Interleukin-5, Eosinophil Cationic Protein, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
